Innovative combination therapy shows promise for bladder cancer patients unresponsive to standard treatment
CORE-001 trial demonstrates efficacy of oncolytic virus and immune checkpoint inhibitor in treating non-muscle invasive bladder cancer
2024-06-06
(Press-News.org) TAMPA, Fla. (June 6, 2024) — In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. Results from the phase 2 CORE-001 trial, published today in Nature Medicine, reveal a significant improvement in complete response rates and long-term disease control, offering new hope for patients with this challenging condition who face limited treatment options.
The trial included patients with BCG-unresponsive carcinoma in situ of the bladder, a condition that is notoriously difficult to treat and often leads to radical cystectomy. The combination therapy of intravesical cretostimogene grenadenorepvec (an intravesically delivered oncolytic immunotherapy) with systemic pembrolizumab (an immune checkpoint inhibitor) demonstrated a complete response rate of 57.1% at 12 months, surpassing previous benchmarks set by other therapies. The trial also demonstrated durable responses; findings show a complete response rate of 82.9% at three months, with a median duration of response not yet reached after a median follow-up of 26.5 months.
"This study marks an important step forward in the treatment of BCG-unresponsive NMIBC," said Roger Li, M.D., principal investigator of the trial and urologic oncologist at Moffitt Cancer Center. "Our findings indicate that the combination of cretostimogene grenadenorepvec and pembrolizumab offers a unique, efficacious and durable bladder-preserving alternative strategy to radical cystectomy."
The oncolytic immunotherapy directly enters the bladder cancer cells, destroys them, and then stimulates an anti-tumor response from the body's immune system. Pembrolizumab, a well-known PD-1 inhibitor, further enhances the immune system's ability to attack cancer cells. The observed clinical benefits stem from the synergistic effect of these two therapies.
"These encouraging results highlight the potential for oncolytic immunotherapy to synergize with immune checkpoint inhibitors, offering a new avenue for patients who have exhausted other treatment options," Li said. "We are optimistic that additional clinical trials will confirm these benefits and support the integration of both monotherapy and combination therapies into the standard-of-care for BCG-unresponsive non-muscle invasive bladder cancer."
The study noted that adverse events were manageable and consistent with those observed in previous monotherapy trials. The most common side effects related to cretostimogene were bladder-related symptoms, while pembrolizumab-related adverse events were typical of systemic immunotherapy.
The trial, funded by CG Oncology (NASDAQ: CGON) in collaboration with Merck, underscores the importance of innovative therapeutic approaches in oncology. Future research will focus on validating these findings in larger cohorts and exploring the underlying mechanisms of action.
For more information about the study, please visit ClinicalTrials.gov.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-06-06
The molecules that make up the matter around us are in constant motion. What if we could harness that energy and put it to use?
Over 150 years ago Maxwell theorized that if molecules’ motion could be measured accurately, this information could be used to power an engine. Until recently this was a thought experiment, but technological breakthroughs have made it possible to build working information engines in the lab.
With funding from the Foundational Questions Institute, SFU Physics professors John Bechhoefer and David Sivak teamed up to build an information engine and test its limits. Their work has greatly advanced ...
2024-06-06
Using artificial intelligence technology to identify patterns of DNA fragments associated with lung cancer, researchers from the Johns Hopkins Kimmel Cancer Center and other institutions have developed and validated a liquid biopsy that may help identify lung cancer earlier.
In a prospective study published June 3 in Cancer Discovery, the team demonstrated that artificial intelligence technology could identify people more likely to have lung cancer based on DNA fragment patterns in the blood. The study enrolled about 1,000 participants with and without cancer who met the criteria for traditional lung ...
2024-06-06
Artificial Intelligence (AI) is the talk of the town, but far too often expediency has been the driver, not responsible innovation. The NYC Media Lab (NYCML) at NYU Tandon School of Engineering and Bertelsmann launched their 4th challenge this month, this time aimed at mentoring teams with projects that use AI to responsibly advance their fields.
The 2024 collaboration, The Ethical Matrix Challenge: Forging New AI Frontiers in Media, Communications, Education, and Healthcare, focuses on ethical AI and its power to have a real-world influence. The four selected teams have projects that can responsibly revolutionize the way ...
2024-06-06
A substantial portion of young athletes are at risk of hypertension, according to a study presented at the American College of Cardiology’s Care of the Athletic Heart conference, taking place on June 6-8 in Washington.
High blood pressure, also known as hypertension, occurs in 47% of adults in the U.S., according to CardioSmart.org. Over time, hypertension weakens the heart, blood vessels and kidneys, paving the way for potential stroke or heart attack. Often referred to as the “silent killer,” high blood pressure is a leading risk factor for heart disease and early death.
The 2017 ACC/American Heart Association Guideline for the Prevention, ...
2024-06-06
While mpox cases have sharply declined since the 2022 global outbreak, they continue to occur in the U.S. among gay and bisexual men who have sex with men (GBMSM), according to a UCLA-led study from EMERGEncy ID NET, a multisite surveillance network funded by the Centers for Disease Control and Prevention (CDC).
Though no cases were found in women, children or the unhoused, vigilance and vaccination remain important, the researchers write.
The findings will be published June 6 in the CDC’s Morbidity and Mortality Weekly Report.
Mpox, formerly known as monkeypox, ...
2024-06-06
How the Cell Cycle Orchestra Plays an Unexpected New Tune
UCSF scientists discover that multiciliated cells adapt the well-known process of cell division to make hundreds of cilia.
The awe-inspiring process of cell division can turn a fertilized egg into a baby – or a cancerous cell into a malignant tumor. With so much at stake, nature keeps it tightly controlled in a process called the cell cycle that scientists thought they thoroughly understood.
But now it turns out there was more to know. Scientists ...
2024-06-06
For every kilogram of matter that we can see — from the computer on your desk to distant stars and galaxies — there are 5 kilograms of invisible matter that suffuse our surroundings. This “dark matter” is a mysterious entity that evades all forms of direct observation yet makes its presence felt through its invisible pull on visible objects.
Fifty years ago, physicist Stephen Hawking offered one idea for what dark matter might be: a population of black holes, which might have formed very soon after the Big Bang. Such “primordial” black holes would not have been the goliaths that we detect today, but ...
2024-06-06
El Centro Regional Medical Center (ECRMC), an affiliate of UC San Diego Health, today announced several financial and operational updates, demonstrating significant progress toward stabilizing and strengthening a critical health services asset in the Imperial Valley.
“Our goal is simple — to ensure that the people of El Centro and the broader Imperial Valley have long-term access to health care services,” said Pablo Velez, RN, PhD, chief executive officer, ECRMC. “Over the last year, the amazing team of dedicated physicians and staff at ECRMC have worked tirelessly in partnership with UC San Diego ...
2024-06-06
Lugano, Switzerland, 6 June 2024 – The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours. The management of rare gynaecological malignancies will be among the key areas covered in the scientific programme, available online.
The congress can be joined either in person or via the online platform.
Programme ...
2024-06-06
BOSTON – Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, marking a crucial step in addressing the heightened cancer risk faced by firefighters.
Dana-Farber’s Direct Connect program partners with employers who want to support their workforce across the spectrum of oncology needs and provides guided access to world-renowned expertise from cancer care specialists. Direct Connect has more than ...
LAST 30 PRESS RELEASES:
[Press-News.org] Innovative combination therapy shows promise for bladder cancer patients unresponsive to standard treatment
CORE-001 trial demonstrates efficacy of oncolytic virus and immune checkpoint inhibitor in treating non-muscle invasive bladder cancer